Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Nagla Abdel Karim, James Schuster, Ihab Eldessouki, Ola Gaber, Tariq Namad, Jiang Wang, Changchun Xie, John C. Morris

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days. Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival. Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.

Original languageEnglish (US)
Pages (from-to)4102-4108
Number of pages7
JournalOncotarget
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2018

Fingerprint

Carcinoma
Lung
Survival
Adjuvant Chemotherapy
Drug Therapy
Therapeutics

Keywords

  • Chemotherapy
  • Lung cancer
  • Non-small cell lung cancer
  • Sarcomatoid

ASJC Scopus subject areas

  • Oncology

Cite this

Karim, N. A., Schuster, J., Eldessouki, I., Gaber, O., Namad, T., Wang, J., ... Morris, J. C. (2018). Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. Oncotarget, 9(3), 4102-4108. https://doi.org/10.18632/oncotarget.23468

Pulmonary sarcomatoid carcinoma : University of Cincinnati experience. / Karim, Nagla Abdel; Schuster, James; Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Xie, Changchun; Morris, John C.

In: Oncotarget, Vol. 9, No. 3, 01.01.2018, p. 4102-4108.

Research output: Contribution to journalArticle

Karim, NA, Schuster, J, Eldessouki, I, Gaber, O, Namad, T, Wang, J, Xie, C & Morris, JC 2018, 'Pulmonary sarcomatoid carcinoma: University of Cincinnati experience', Oncotarget, vol. 9, no. 3, pp. 4102-4108. https://doi.org/10.18632/oncotarget.23468
Karim NA, Schuster J, Eldessouki I, Gaber O, Namad T, Wang J et al. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. Oncotarget. 2018 Jan 1;9(3):4102-4108. https://doi.org/10.18632/oncotarget.23468
Karim, Nagla Abdel ; Schuster, James ; Eldessouki, Ihab ; Gaber, Ola ; Namad, Tariq ; Wang, Jiang ; Xie, Changchun ; Morris, John C. / Pulmonary sarcomatoid carcinoma : University of Cincinnati experience. In: Oncotarget. 2018 ; Vol. 9, No. 3. pp. 4102-4108.
@article{6a273e4d99364fd59332a53e210c1cc4,
title = "Pulmonary sarcomatoid carcinoma: University of Cincinnati experience",
abstract = "Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days. Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival. Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.",
keywords = "Chemotherapy, Lung cancer, Non-small cell lung cancer, Sarcomatoid",
author = "Karim, {Nagla Abdel} and James Schuster and Ihab Eldessouki and Ola Gaber and Tariq Namad and Jiang Wang and Changchun Xie and Morris, {John C.}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23468",
language = "English (US)",
volume = "9",
pages = "4102--4108",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - Pulmonary sarcomatoid carcinoma

T2 - University of Cincinnati experience

AU - Karim, Nagla Abdel

AU - Schuster, James

AU - Eldessouki, Ihab

AU - Gaber, Ola

AU - Namad, Tariq

AU - Wang, Jiang

AU - Xie, Changchun

AU - Morris, John C.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days. Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival. Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.

AB - Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days. Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival. Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.

KW - Chemotherapy

KW - Lung cancer

KW - Non-small cell lung cancer

KW - Sarcomatoid

UR - http://www.scopus.com/inward/record.url?scp=85040177632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040177632&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23468

DO - 10.18632/oncotarget.23468

M3 - Article

AN - SCOPUS:85040177632

VL - 9

SP - 4102

EP - 4108

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -